Bevacizumab (Lumiere®) — Competitive Intelligence Brief

Bevacizumab (Lumiere®) (Bevacizumab (Lumiere®)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (anti-VEGF). Area: Oncology.

phase 3 Monoclonal antibody (anti-VEGF) VEGF (Vascular Endothelial Growth Factor) Oncology Small molecule

Target snapshot

Bevacizumab (Lumiere®) (Bevacizumab (Lumiere®)) — Laboratorio Elea Phoenix S.A.. Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bevacizumab (Lumiere®) TARGET	Bevacizumab (Lumiere®)	Laboratorio Elea Phoenix S.A.	phase 3	Monoclonal antibody (anti-VEGF)	VEGF (Vascular Endothelial Growth Factor)
Triamcinolone + Bevacizumab	Triamcinolone + Bevacizumab	Rubens Belfort Jr.	marketed	Corticosteroid + Monoclonal antibody (anti-VEGF)	Glucocorticoid receptor; VEGF (vascular endothelial growth factor)
Bevacizumab and Capecitabine	Bevacizumab and Capecitabine	Central European Cooperative Oncology Group	phase 3	Combination therapy: monoclonal antibody (anti-VEGF) and fluoropyrimidine chemotherapy	VEGF (bevacizumab); thymidylate synthase (capecitabine)
FOLFOXIRI + Bevacizumab	FOLFOXIRI + Bevacizumab	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	phase 3	Chemotherapy combination + monoclonal antibody (anti-VEGF)	DNA (chemotherapy); VEGF (bevacizumab)
Bevacizumab and Pemetrexed/platinum	Bevacizumab and Pemetrexed/platinum	Sun Yat-sen University	phase 3	Combination therapy: monoclonal antibody (anti-VEGF) + antifolate + platinum chemotherapy	VEGF (bevacizumab); thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase (pemetrexed); DNA (platinum)
Bevacizumab, Cyclophosphamide, Capecitabine	Bevacizumab, Cyclophosphamide, Capecitabine	Swiss Cancer Institute	phase 3	Combination therapy: monoclonal antibody (anti-VEGF) + chemotherapy	VEGF (vascular endothelial growth factor) for bevacizumab; DNA for cyclophosphamide and capecitabine
Bevacizumab + Pemetrexed + Carboplatin	Bevacizumab + Pemetrexed + Carboplatin	PD Dr. med. Wolfgang Schuette	phase 3	Combination therapy: monoclonal antibody (anti-VEGF) + antifolate chemotherapy + platinum chemotherapy	VEGF (bevacizumab); thymidylate synthase and other folate-dependent enzymes (pemetrexed); DNA (carboplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (anti-VEGF) class)

1. Laboratorio Elea Phoenix S.A. · 1 drug in this class